Internal Medicine, Hematology & Oncology · Dallas, TX
NPI
1578810370
Since 2012
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
5323 Harry Hines Boulevard
Dallas, TX, 75390
Phone (214) 590-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$43K
392 services
Medicare patients, 2024
108
Average age 72
Drug cost, 2024
$1.5M
777 prescriptions
Company payments, 2025
$4,367
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Syed M Kazmi was code 99215 (office e&m - established), 200 times for 60 patients. In total Syed M Kazmi billed 392 services in 7 codes, and Medicare paid $43K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-08-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 200 | 60 | $110.70 | $22K |
| 99215 Office E&M - Established | Office | 95 | 47 | $124.52 | $12K |
| 99214 Office E&M - Established | Facility | 39 | 34 | $75.62 | $2,949 |
| 99214 Office E&M - Established | Office | 26 | 24 | $74.45 | $1,936 |
| 99205 Office E&M - New | Facility | 11 | 11 | $138.28 | $1,521 |
By year: 2022 $57K for 579 services; 2023 $31K for 475 services; 2024 $43K for 392 services.
Medicare prescription drug claims, 2024
In 2024, the drug Syed M Kazmi prescribed most often to Medicare patients was Lonsurf (Trifluridine/Tipiracil Hcl), with 85 prescriptions and refills. In total Syed M Kazmi wrote 777 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lonsurf Trifluridine/Tipiracil Hcl | 85 | 85 | Under 11 | $718K |
| Prochlorperazine Maleate Generic | 71 | 71 | 29 | $591 |
| Ondansetron Hcl Generic | 41 | 44 | 21 | $327 |
| Dexamethasone Generic | 37 | 41 | 14 | $395 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 33 | 37 | 11 | $591 |
| Loperamide Loperamide Hcl | 31 | 33 | 12 | $323 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 30 | 30 | 13 | $1,174 |
| Eliquis Apixaban | 28 | 32 | Under 11 | $19K |
| Gabapentin Generic | 28 | 32 | Under 11 | $664 |
| Pantoprazole Sodium Generic | 27 | 61 | 12 | $154 |
| Potassium Chloride Generic | 23 | 35 | 11 | $337 |
| Creon Lipase/Protease/Amylase | 21 | 22 | Under 11 | $78K |
| Alprazolam Generic | 18 | 19 | Under 11 | $62.03 |
| Tramadol Hcl Generic | 17 | 17 | Under 11 | $69.26 |
| Levothyroxine Sodium Generic | 14 | 40 | Under 11 | $232 |
Brand drugs: 199 claims; generic drugs: 578 claims; opioid claims: 78.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Syed M Kazmi $4,367 ($4,367 in general payments such as food, travel and fees) from 11 companies. The largest payer was Taiho Oncology, Inc. with $4,064.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.